- The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Nash, J.E., Ravenscroft, P., McGuire, S., Crossman, A.R., Menniti, F.S., Brotchie, J.M. Exp. Neurol. (2004)